Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05735912 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EUS-RFA Versus Surgery for Pancreatic Insulinoma (ERASIN-RCT)

Study acronym: ERASIN-RCT
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Feb 28, 2026 to Oct 31, 2028
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Feb 28, 2029 to Oct 31, 2028
    • Site details revised
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruitingv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this muticentre randomized controlled trial is to compare endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) with surgery for treatment of pancreatic insulinoma. The main questions it aims to answer are: 1) What is the safest treatment? 2) Is efficacy comparable? Patients will be randomized to undergo EUS-RFA or surgical resection. Researchers will compare the rate of adverse events and the clinical efficacy after the two treatments to see if EUS-RFA result safer and effective compare with surgery.
Trial Details
NCT Number NCT05735912
Lead Sponsor Azienda Ospedaliera Universitaria Integrata Verona
Conditions
(from sponsor)		 Pancreatic Insulinoma
Related terms Insulinoma
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov